The nuclear imaging market is experiencing a transition towards increased use and development of positron emission tomography (PET) scans, particularly in oncology and other high-value applications. A report by GlobalData forecasts that the global PET imaging agent market will be valued at $2.1 billion by 2025, growing at a 4.6% compound annual growth rate. This growth is attributed to innovations in tracer development and advances in imaging technology, including the rise of theranostics, which combine diagnostic and therapeutic elements. Meanwhile, single-photon emission computed tomography (SPECT) remains important in nuclear medicine, particularly for its established infrastructure and lower equipment costs, but is projected to grow at a slower rate. The market is seeing an active development pipeline with 129 PET agents compared to only 14 for SPECT, indicating a shift towards broader adoption of PET, especially in high-income markets. However, challenges such as supply fluctuations and training demands may affect adoption rates in various regions.
Thu, 21 Aug 2025 14:32:59 GMT | Medical Device Network